Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma

BACKGROUND: Despite significant therapeutic advances over the last decade, multiple myeloma remains an incurable disease. Pomalidomide is the third Immunomodulatory drug that is commonly used to treat patients with relapsed/refractory multiple myeloma. However, approximately half of the patients exh...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Yan, Li, Chenyu, Jiang, Hua, Li, Lu, Zhang, Yuanteng, Yu, Wei, Fu, WeiJun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549987/
https://www.ncbi.nlm.nih.gov/pubmed/37799465
http://dx.doi.org/10.3389/fonc.2023.1264422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549987/
https://www.ncbi.nlm.nih.gov/pubmed/37799465
http://dx.doi.org/10.3389/fonc.2023.1264422

Ejemplares similares